Pipeline

Rebiotix is pioneering Microbiota Restoration Therapy (MRT) which has the potential to change the way challenging diseases are treated.

Lead MRT product, RBX2660 is targeted at treating recurrent Clostridium difficile (C. diff.) infection. We are leveraging our years of knowledge and experience to develop MRT applications for other conditions that result from disruption of the gut microbiota.

Pipeline: RBX2660 – Enema Formulation

Indication
Phase 1
Dosing
Phase 2a / b
Phase 3
Next Milestone
  • Confirmatory Phase 3 study: H2 2017

VRE EliminationPhase I

  • Completed Proof-of-Concept
  • Published results
  • In process
  • Clinical data readout expected 2017
  • Proof-of-concept
  • Proof-of-concept
  • Clinical data readout expected 2017

Pipeline: RBX7455 – Oral Formulation

Indication
Phase 1
Dosing
Phase 2a / b
Phase 3
Next Milestone
  • Dosing Proof-of-concept
  • Data mid-2017

Caution: Drug products are in development and investigational at this time. No product has yet been approved by the U.S. Food and Drug Administration.